Abstract
Formulation of Oxybutynin Chloride (OBC) matrix tablets offers good controlled release and less anticholinergic adverse effects in the treatment of overactive bladder (OAB) besides this it also reduces the dosage frequency. Matrix tablets were formulated by using HPMC K4M, HPMC K100M, Carbopol, Polyvinyl pyrrolidine (PVP), Ethylcellulose (EC) and Sodium alginate (SA) as release controlling polymers for 24 h by using direct compression method. For confirmation of compatibility, the pure drug and its physical mixtures were subjected to FTIR studies. All the formulations have shown acceptable limits in all precompression and post compression parameters. Dissolution studies of all the formulation were studied for 24 h, first 2h using 0.1N HCl and 6.8phosphate buffer for the remaining duration and found that formulation F8 with HPMC K4M has shown good controlled release for 24 h with cumulative release of 95.59% of drug release. From the kinetic studies, it was observed that formulation F8 showed first order drug release with the mechanism of drug release of non fickian diffusion.
